Comparative Pharmacology
Head-to-head clinical analysis: ALREX versus VEXOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALREX versus VEXOL.
ALREX vs VEXOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory mediators.
Selective glucocorticoid receptor agonist; binds to cytoplasmic receptors leading to inhibition of phospholipase A2, suppression of inflammatory mediators, and vasoconstriction.
1-2 drops in the affected eye(s) four times daily; in severe cases, may be increased to 1-2 drops every hour during the first 24-48 hours.
1-2 drops of 1% ophthalmic suspension in the conjunctival sac of the affected eye(s) four times daily. In severe conditions, may increase frequency to every 2 hours during initial 24-48 hours.
None Documented
None Documented
Approximately 1.6 hours (range 1.2–2.2 hours) for the active metabolite loteprednol etabonate; short half-life allows for BID dosing with minimal systemic accumulation.
Terminal elimination half-life is approximately 2.3 hours in adults. This short half-life supports twice-daily dosing for maintenance of therapeutic effect.
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Fecal elimination accounts for the remainder via biliary excretion.
Primarily hepatic metabolism with biliary excretion of metabolites. Renal excretion accounts for <2% of unchanged drug. Fecal elimination of metabolites is the major route (>90%).
Category C
Category C
Corticosteroid (Ophthalmic)
Corticosteroid (Ophthalmic)